Supplementary protection
LT - Ponezimodo, selektyviojo S1P1 receptorių agonisto, dozavimo režimas
EN - DOSING REGIMEN FOR PONESIMOD, A SELECTIVE S1P1 RECEPTOR AGONIST
SPC
| (11) |
Number of the document |
C 3256125 |
| (68) |
Number of the document |
3256125
|
| (21) |
Application number for Supplementary Protection Certificate |
PA 2022 505 |
| (22) |
Date of filing the application |
2022-05-20 |
| (41) |
Date of publication of the application |
2022-06-10 |
|
Date of publication of SPC |
2024-03-12 |
| (24) |
Date of coming into effect of SPC |
2035-12-11 |
Applicant
| (71) |
Actelion Pharmaceuticals Ltd ,
Gewerbestrasse 16, 4123 Allschwil,
CH
|
Grantee
| (73) |
Laboratoires Juvise Pharmaceuticals ,
149, Boulevard Bataille de Stalingrad, 69100 Villeurbanne,
FR
|
Attorney or representative
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
Number, date and code of the country of origin of the first authorization to place the medicinal or plant protection product on the market within regional economic community
| (93) |
EU/1/21/1550, 2021-05-19
|
Calculated date of expiry of the SPC
| (94) |
2036-05-21 |
Name of the product protected by the basic patent
| (95) |
Ponezimodas |
